US Patents With Foreign Priority to India Patent: 2692/CHE/2012
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tg Theraps | UKONIQ | umbralisib tosylate | TABLET;ORAL | 213176-001 | Feb 5, 2021 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN | ||||
| Tg Theraps | UKONIQ | umbralisib tosylate | TABLET;ORAL | 213176-001 | Feb 5, 2021 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY | ||||
| Tg Theraps | UKONIQ | umbralisib tosylate | TABLET;ORAL | 213176-001 | Feb 5, 2021 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN | ||||
| Tg Theraps | UKONIQ | umbralisib tosylate | TABLET;ORAL | 213176-001 | Feb 5, 2021 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
